Modelling how ribavirin improves interferon response rates in hepatitis C virus infection (Q42989468)

12 November 2017

Modelling how ribavirin improves interferon response rates in hepatitis C virus infection (English)

1 reference

12 November 2017

1 reference

1 reference

1 reference

4

Alan S Perelson

1 reference

12 November 2017

Narendra M Dixit

1

1 reference

12 November 2017

Jennifer E Layden-Almer

series ordinal

2

1 reference

12 November 2017

Thomas J Layden

series ordinal

3

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 December 2004

1 reference

12 November 2017

1 reference

12 November 2017

432

1 reference

12 November 2017

7019

1 reference

12 November 2017

922-924

1 reference

https://scigraph.springernature.com/pub.10.1038/nature03153

12 November 2017

0 references

cites work

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03153

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03153

Hepatitis C therapeutics: current status and emerging strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03153

A randomized, controlled trial to determine whether continued ribavirin monotherapy in hepatitis C virus-infected patients who responded to interferon-ribavirin combination therapy will enhance sustained virologic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03153

Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03153

Mechanism of action of ribavirin in the combination treatment of chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03153

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03153

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03153

Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03153

Antiviral action of ribavirin in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03153

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03153

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03153

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03153

Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03153

Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03153

Ribavirin Induces Error-Prone Replication of GB Virus B in Primary Tamarin Hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03153

RNA virus error catastrophe: direct molecular test by using ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03153

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03153

Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03153

Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03153

Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03153

Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03153

7 January 2021

The role of ribavirin-induced mutagenesis in HCV therapy: A concept or a fact?

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03153

7 January 2021

Viral dynamics and pharmacokinetics in combined interferon alfa-2b and ribavirin therapy for patients infected with hepatitis C virus of genotype 1b and high pretreatment viral load

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03153

7 January 2021

The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03153

7 January 2021

Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon alfa-2b

1 reference

https://api.crossref.org/works/10.1038%2FNATURE03153

7 January 2021

Identifiers

DOI

10.1038/NATURE03153

1 reference

Dimensions Publication ID

12 November 2017

0 references

1 reference